ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IMUN Immune Therapeutics Inc (PK)

0.093
0.00 (0.00%)
06 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Immune Therapeutics Inc (PK) USOTC:IMUN OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.093 0.072 0.10 0.00 01:00:00

Immune Therapeutics, Inc. to Hold an Informational Shareholder Meeting on Wednesday, August 17, 2016 at 10 A.M. EDT

26/07/2016 7:17pm

Marketwired


Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Immune Therapeutics (PK) Charts.

Immune Therapeutics, Inc. to Hold an Informational Shareholder Meeting on Wednesday, August 17, 2016 at 10 A.M. EDT

ORLANDO, FL-(Marketwired - Jul 26, 2016) - Immune Therapeutics, Inc. (OTCQB: IMUN) An Informational Shareholder Meeting will be held on Wednesday, August 17, 2016, at 10 a.m. EDT, at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, FL 32801.

An archive of the Informational Shareholder Meeting will be available on the Immune Therapeutics' website by Monday, August 22, 2016 at www.immunetherapeutics.com.

In order to attend the Shareholder Meeting you must be a shareholder of record or a beneficial owner of Immune Therapeutics, Inc. stock as of the close of business on August 16, 2016.

The meeting is for shareholders only.

About Immune Therapeutics:

Immune Therapeutics, formerly known as TNI BioTech, Inc., is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using its patented immunotherapy. Its products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Immune Therapeutics' proprietary technology, therapies and patents include the treatment of a wide range of cancers. Its most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or Lodonal, which have been shown to stimulate the immune system even in patients with advanced cancer.

ContactAmato and Partners, LLCInvestor Relations Counsel90 Park Avenue. 17th FloorNew York, NY 10016admin@amatoandpartners.com

1 Year Immune Therapeutics (PK) Chart

1 Year Immune Therapeutics (PK) Chart

1 Month Immune Therapeutics (PK) Chart

1 Month Immune Therapeutics (PK) Chart

Your Recent History

Delayed Upgrade Clock